Comparative Pharmacology
Head-to-head clinical analysis: ELLENCE versus VALSTAR PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELLENCE versus VALSTAR PRESERVATIVE FREE.
ELLENCE vs VALSTAR PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ELLENCE (epirubicin) is an anthracycline cytotoxic antibiotic. It intercalates between DNA base pairs, inhibits topoisomerase II activity, and generates free radicals, leading to DNA damage and cell death.
Valrubicin is a semisynthetic anthracycline derivative that intercalates into DNA, inhibiting nucleic acid synthesis and inducing cell death. It is cytotoxic to both dividing and non-dividing cells.
60-120 mg/m2 IV bolus or slow infusion on Day 1 every 21-28 days; or 20-30 mg/m2 IV daily for 3 days repeated every 28 days.
Intravesical instillation of 800 mg (40 mL of 20 mg/mL solution) weekly for 6 weeks, retained in bladder for 2 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 20-40 hours (mean ~30 hours). This supports a 3-week dosing interval to allow for recovery from myelosuppression.
Terminal elimination half-life: 3-5 hours; clinical context: supports intravesical instillation with minimal systemic absorption.
Primarily hepatobiliary excretion: ~40-50% of dose excreted as unchanged drug and metabolites in bile and feces. Renal excretion accounts for <10% (mostly as metabolites).
Renal: approximately 50-70% excreted unchanged in urine within 72 hours; biliary/fecal: minor (<5%).
Category C
Category C
Anthracycline Antineoplastic
Anthracycline Antineoplastic